Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas
Year: 2025
Type: article
Source: Clinical Cancer Research
Authors: Kevin J. Harrington, Stephane Champiat, Joshua D. Brody, Byoung Chul Cho, Emanuela Romano, Talia Golan, John R. Hyngstrom, James Strauss, David Y. Oh, Aron Popovtzer, Carlos Gomez-Roca, Ruth Perets, Sung-Bae Kim, Deborah J. Wong, Steven F. Powell, Anuradha Khilnani, Thomas Jemielita, Qing Zhao, Runchen Zhao, Matthew Ingham
Institutions: Institute of Cancer Research, The University of Texas MD Anderson Cancer Center, Inserm, Institut Gustave Roussy, Immunologie anti-tumorale et immunothérapie des cancers, Fondation Gustave Roussy, Icahn School of Medicine at Mount Sinai, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Université Paris Sciences et Lettres, Institut Curie, Tel Aviv University, Sheba Medical Center, University of Utah, Huntsman Cancer Institute, Mary Crowley Cancer Research Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Hadassah Medical Center, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, Technion – Israel Institute of Technology, Rambam Health Care Campus, Asan Medical Center, University of Ulsan, University of California, Los Angeles, Sanford Research, Merck & Co., Inc., Rahway, NJ, USA (United States), EMD Serono, Inc. (United States), Columbia University Irving Medical Center, Columbia University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4411199770